Atlas Venture unveils a $280M pure play biotech startup fund

John Carroll Squarely focused on seeding and nurturing biotech startups and armed with some of the best relationships in the business, Atlas Venture is unveiling a new $ 280 million ...

BMS, focused on immuno-oncology, turns Erbitux over to Eli Lilly

Eric Palmer Erbitux is one of the top 10 best selling cancer drugs in the world and for years Bristol-Myers Squibb has sold it in the U.S. But Erbitux no longer fits in the sweet spot ...

Israel awaits $250M fund, ThromboGenics spins out oncology asset, MolMed licenses CAR-T

Nick Paul Taylor In this week's EuroBiotech Report, OrbiMed Advisors is in the early stages of preparing a second Israel-focused fund that could transfer $ 250 million (€235 ...

GSK closing Pittsburgh office, putting 275 jobs at risk

Eric Palmer The big asset swap between GlaxoSmithKline and Novartis may have given each just what it wanted, but the deal continues to play out poorly for workers, with GSK planning ...

Medicines Co.’s cangrelor finally lines up for FDA approval

Damian Garde A panel of FDA advisers reversed its earlier derision and voted in favor of the Medicines Company's long-delayed blood thinner, spelling a likely approval for the drug ...

Sanofi expands PA vaccine facility to prepare for dengue launch

Tracy Staton Sanofi plans to manufacture its highly anticipated dengue vaccine in a French facility built specifically for the product. But Sanofi Pasteur's vaccine operation in ...

Argos gets a $40M China deal for AGS-003

John Carroll China's Lummy HK and the China BioPharma Capital I Fund have agreed to acquire $ 10 million worth of Durham, NC-based Argos Therapeutics stock in exchange for rights ...

Takeda taps Lilly exec to run U.S. unit, adding a woman to its all-male exec team

Tracy Staton Takeda has chosen a woman to run its U.S. pharma business, just weeks after new CEO Christophe Weber said he was unhappy with the gender balance in the Japanese drugmaker's ...

Galapagos’ closely watched rheumatoid arthritis drug filgotinib scores in PhIIb

John Carroll Belgium's Galapagos says that its oral JAK1 inhibitor filgotinib met its primary and other endpoints in a crucial Phase IIb study for rheumatoid arthritis. FierceBiotech ...

Onglyza’s label should flag heart failure risks, FDA panel says

Tracy Staton AstraZeneca escaped the worst with an FDA panel vote on Onglyza. The agency's expert advisers almost unanimously backed the drug's cardiovascular safety. But the ...

Celgene buys into Mesoblast’s stem cell pipeline in regenerative med pact

John Carroll Celgene has stepped up with a deal to buy a $ 45 million chunk of Mesoblast's stock at a premium price in exchange for a front row seat on the Australian biotech's ...

Vertex’s Kalydeco combo could run payers $10M-plus per life, PBM figures

Carly Helfand Sky-high drug prices have been causing their fair share of consternation among payers lately, and industry watchers have suspected for a while now that Vertex will stir ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS